Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2
IL-2 is used systemically for cancer therapy but it is associated with severe toxicity. Here, the authors design a recombinant vaccinia virus expressing membrane-bound IL-2 that shows therapeutic efficacy alone or in combination with checkpoint inhibitors in colon cancer-bearing mice.
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-11-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-018-06954-z |